We have developed a sensitive assay for the measurement of alanine:glyoxylate aminotransferase (EC 2.6.1.44) activity in human liver. The assay is partly automated, and takes into consideration the sensitivity of the reaction to pH and to glyoxylate concentration. It is less subject to interference from other enzymes utilizing glyoxylate and to chemical interference from glyoxylate itself and can therefore be used without correction for cross-over by glutamate:glyoxylate aminotransferase (EC 2.6.1.4). The assay allows clear discrimination between normal and affected livers and is sufficiently sensitive to measure enzyme activity in fetal liver samples. Enzyme activity ranged from 17·9 to 38'5/lmol/h/mg protein in control livers (n = 9) and 0·8 to 9·5 /lmol/h/mg protein in 30 of 39 hyperoxaluric patients studied. Normal alanine: glyoxylate aminotransferase activity (from 22·8 to 45·5/lmol/h/mg protein) allowed exclusion of primary hyperoxaluria type I in the other nine hyperoxaluric patients.
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Primary hyperoxaluria type I (PHI) is an inherited disorder of glyoxylate metabolism characterized by increased endogenous oxalate production, nephrocalcinosis, urolithiasis and (in the most severe form) systemic oxalosis and death within the first year of life from the complications of renal failure. PHI is caused by a deficiency of the hepatic peroxisomal enzyme alanine:glyoxylate aminotransferase (AGT), a pyridoxal 5'-phosphate (PLP) dependent enzyme which catalyses the conversion of glyoxylate to glycine.' When AGT activity is deficient, glyoxylate is metabolized to oxalate, either in the peroxisomes by the enzyme glyoxylate oxidase or after diffusion into the cytosol where it acts as a substrate for lactate dehydrogenase (LDH).
Definitive diagnosis of PHI requires measurement of AGT catalytic activity and immunoreactivity in a liver biopsy and, in some cases, immunolocalization to detect mitochondrial mistargeting of the enzyme.? The methods reported in the literature offer a variety of reaction conditions for the measurement of this Correspondence Dr G Rumsby. 400 enzyme and there is continuing debate as to the best way of correcting for interference by other enzymes, including the use of correction factors,' immunoprecipitation and enzyme inhibitors." However, no consensus has been reached. We therefore decided to re-evaluate the conditions for the AGT and glutamate:glyoxylate aminotransferase (GGT) assays and we report a semi-automated method for AGT activity determination which can be used for the tissue diagnosis of PHI, without correction.
MATERIALS AND METHODS
All reagents were purchased from Sigma Chemical Co (Poole, UK).
Preparation and processing of liver biopsy material Biopsy samples were obtained from 12 normal subjects and 39 hyperoxaluric individuals. Fetal liver samples were kindly supplied by Dr C Danpure and were as previously described. Samples were stored frozen at either -20°C or -70°C until analysis' A 2% (w/v) suspension was prepared by adding a weighed amount of tissue to a minimum volume of 400/lL 
Optimization and validation of AGT and GGT assays
The basic assay conditions were adapted from those previously described.! Fifty microlitres of sonicate was mixed with 50 JlL of 100mmoljL phosphate butTer and 100JlL of glyoxylate, and the reaction was started by the addition of the appropriate second substrate (alaninejPLP and glutarnate/Pl.P for AGT and GGT, respectively). The reaction was allowed to proceed at 37"C for 60 min, then stopped by the addition of 50 JlL 50% (wjv) trichloroacetic acid (TCA). The tubes were placed on ice. For both AGT and GGT assays a tissue control was included by omitting glyoxylate until after the TCA addition. Following centrifugation for 5 min at I2,000 g in a microcentrifuge, the pyruvate (from the AGT reaction) and oxoglutarate (from GGT) in the supernatant were determined on a Cobas Bio centrifugal analyser (Roche Diagnostic Systems, Welwyn Garden City, UK) using lactate dehydrogenase/NADH and glutamate dehydrogenase/NADH reaction systems as summarized in Table I. 100mrnol/L potassium dihydrogen/dipotassium hydrogen phosphate butTer, pH 8·0 containing 240 mrnol/L sucrose and 0·1 mmol/L PLP. The suspension was sonicated on ice, using four cycles of alternate lOs bursts and 30 s rests with a Microson XL sonicator (Labcaire Systems Ltd, Clevedon, UK) to achieve a uniform suspension.
Following centrifugation for 10 min at 2000g in a microcentrifuge, the supernatant, containing approximately 2 mg/ mL protein, was used for the AGT and GGT studies. In addition, every sonicate was subjected to assay of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in an attempt to confirm its hepatic origin.
The presence of immunoreactive AGT protein was determined by western blotting using rabbit antihuman AGT antiserum (obtained from Dr C J Danpure, Department of Biology, University College London). Bound antibodies were visualized with alkaline phosphatase conjugated to goat antirabbit IgG (BioRad Laboratories Ltd, Hemel Hempstead, UK).
ALrand AST 7 activities in the sonicated biopsy samples were determined, after ten-fold dilution with normal saline, by automated optimized assays used in the department for the routine assay of serum samples. Protein was determined by the method of Lowry" using bovine serum albumin as standard.
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Long-term between-batch imprecision studies were not practicable due to the instability of AGT in frozen sonicates, (in our experience AGT decreases by approximately 15% over a I month period).
Assay imprecision
The within-batch coefficient of variation of 10 replicates was 2·7% for AGT and 5·4% for GGT at activities of 20·0 and 1·1 Jlmol/h/mg protein, respectively.
RESULTS
Optimization and validation of AGT and GGT assays pH optima The pH profiles are shown in Fig. I . AGT showed optimal activity between 7,8-8,0 while GGT was relatively insensitive to pH over the range tested. Subsequent analyses were performed at pH 8·0 for both enzyme assays.
Optimal substrate concentrations
The substrate concentrations are summarized in Table 2 . The glyoxylate concentration chosen was a compromise in an attempt to minimize the substrate inhibition in the AGT assay documented by other workers-? and confirmed in our laboratory (data not shown).
Linearity of reaction
The reaction rate for both enzymes remained linear across the 60 min incubation period and in response to increasing amounts of enzyme protein. The Cobas Bio assays for pyruvate and oxoglutarate were able to cope with concentrations of these products up to 4 mmol/ L, well in excess of those generated during assay of a typical normal liver sample.
Minimal detectable activity
The minimal detectable activity, defined as the activity corresponding to three standard deviations above the rate at the point where no further fall in activity could be discerned, was 0·64 Jlmol/h/mg protein and 0·62 Jlmol/h/mg protein for AGT and GGT, respectively.
Enzyme measurements in patient and control samples
Using the optimized assay AGT activity in the nine normal livers ranged from 17·9 to 38·5 Jlmol/h/mg protein [mean 27·9 (SD 7, 9) ]. GGT activity in the same samples ranged from 0·8-2·0 Jlmol/h/mg protein [mean 1·4 (SD 0,39)]. At such low GGT levels, correction for interference in the AGT reaction is unnecessary.
In the 39 hyperoxaluric individuals two subgroups were evident (Fig. 2 ). Thirty individuals clearly had deficient AGT activity with values ranging from 0·8-9'5 Jlmol/h/mg protein, supported by the finding of immunoreactive AGT specific protein at less than an estimated 25% of normal. The remaining nine subjects had AGT activities from 22·8 to 45·5 Jlmol/h/mg protein, within the reference range, and an associated normal level of immunoreactive protein. In five of these nine the diagnosis of PHI was subsequently thought unlikely on clinical grounds and one further subject was diagnosed as having primary hyperoxaluria type 2. The hyperoxaluria remained unexplained in three subjects.
The method was sufficiently sensitive to measure AGT activity in a normal liver using as little as 2·5 ug of protein per tube. This is adequate for the measurement of AGT activity in fetal liver from which only a small amount of material is available. The AGT activity in 10 fetal samples was lower than in postnatal samples and ranged from 0·9-15·1 Jlmol/h/mg protein.
Calculation 0·8)]. One patient's sample with AGT activity of 1'5/lmoljhjmg protein and no immunoreactive protein was found to have a very high AST:ALT ratio of 18,8, raising the possibility of a nonhepatic origin for this biopsy. This suspicion was confirmed by detection of some AGT on immunogold electron microscopy. The true value of hepatic AGT in this patient awaits a repeat biopsy.
DISCUSSION
The definitive diagnosis of PH I requires a reliable assay for liver AGT activity, but there is little agreement in the literature on the best mechanism for overcoming some of the intrinsic problems associated with the assay of this enzyme. The reaction conditions are compromised by the highly unstable and reactive nature of glyoxylate. This substrate was shown to inhibit the AGT reaction at final concentrations greater than 10mmoljL, necessitating the use of a concentration less than the ideal concentration predicted from a knowledge of the K m , confirming the finding of others':" but in contrast to the method initially adopted in this laboratory which used a glyoxyate concentration of 50 mmoljL. 3 It should also be noted that any glyoxylate remaining after the incubation period for the AGT assay must be removed prior to the subsequent pyruvate assay since glyoxylate is a substrate for LDH. 1O This is easily achieved by addition of Tris buffer prior to pyruvate assay, a precaution adopted throughout this study. The K m values for alanine and glyoxylate obtained at pH 8·0 compared favourably with those determined previously.?:'! The use of the optimal pH (8'0) for AGT measurements and the optimized glyoxylate concentration means that our proposed method yields higher specific activities in control samples than those previously obtained.' The AGT activity in controls analysed in the present study was slightly higher than previously published results for assays with similar conditions.Pi'! These discrepancies may be accounted for by differences in the protein method used and also in the smaller number of samples reported in these studies.
The other major area of debate in respect of AGT assays is the need to correct for the effect of other glyoxylate utilizing enzymes, notably GGT, traditionally based on a separate assay of this enzyme and application of a derived 'correction factor'. In recent years other solutions to this problem have been proposed, most recently the use of aminooxyacetic acid as a selective inhibitor of AGT. 4 In our experience this substance also inhibits GGT, ALT and AST activities, raising doubts over its specificity. In addition, there is also the risk of accidental cross-contamination of test samples with this powerful inhibitor and we therefore consider this approach less than desirable. In practice, using the optimized assay conditions described here, we have found the GGT activities to be so low as to make any correction unnecessary. There is excellent discrimination between normal and affected samples. The GGT activity in AGT immunonegative samples accounts for less than 8% of mean AGT activity in controls. We find the use of the AST:ALT ratio (which uses very little sonicate volume) a valuable confirmation that a sample is hepatic in origin.
The assay system we have described has good precision for both AGT and GGT, partly due to the automation of the product assay stage. Other workers have used fully automated procedures for AGT although the interaction of Tris with oxoglutarate was reported to prevent full automation of the GGT assay." We have found no evidence for the interference Rumsby, Weir and Samuel! of Tris with oxoglutarate measurement (data not shown) and use this buffer for both pyruvate and oxoglutarate determinations, minimizing the number of solutions required in the assays. The procedure as described is sensitive enough to allow AGT estimations on the small samples collected via fetal liver biopsy. Our data shows that definition of a fetal reference range would be necessary if this approach were to be considered for pre-natal diagnosis of PH 1. Recent advances in DNA analysis'? have effectively superseded liver enzyme assay for this purpose.
CONCLUSION
We present a modified method for the measurement of AGT in liver biopsies. The method is semi-automated, precise, requires no correction for interference by other enzymes and gives good discrimination between normal and affected individuals.
